Shanghai Henlius Biotech, Inc.: history, ownership, mission, how it works & makes money

From its origins within Fosun's pharma arm to a publicly listed biotech and now a strategic takeover target, Shanghai Henlius Biotech reads like a modern biotech playbook: founded in 2010 to develop biosimilars, listed in Hong Kong in 2019, and by 2024 delivering a 6.1% rise in total revenue to about RMB5,724.4 million and a second consecutive profitable year with net profit of RMB820.5 million; today Henlius-65.23% owned by Fosun through Shanghai Fosun Pharmaceutical-was the subject of a June 2024 buyout offer valuing the group at roughly HK$13.37 billion (HK$24.60/share, a 30.6% premium), while operationally it has launched six products in China and four abroad, reached over 850,000 patients across nearly 60 countries, runs GMP-certified manufacturing and global innovation centers, manages a pipeline of about 50 molecules with 30+ clinical studies, and monetizes growth via drug sales, R&D services and licensing partnerships with over 20 global firms.

Shanghai Henlius Biotech, Inc. (2696.HK): Intro

• 1992: Four entrepreneurs established Fosun Group, which later created Fosun Pharmaceuticals in 1994 to address China's growing healthcare needs.
• 2010: Fosun Pharmaceuticals, together with two scientists, founded Shanghai Henlius Biotech to develop biosimilars and promote affordable alternatives to originator biologics.
• 2019: Henlius listed on the Hong Kong Stock Exchange (ticker: 2696.HK), a key milestone enabling broader capital access for global expansion and R&D.
• 2024: Henlius reported total revenue of approximately RMB 5,724.4 million, a 6.1% year‑over‑year increase driven by drug sales and R&D services.
• 2024: Net profit reached RMB 820.5 million, representing the company's second consecutive year of profitability.
• As of 2025: Henlius has launched six products in China and four internationally, with its medicines benefiting over 850,000 patients across nearly 60 countries and regions.

• Founding and strategic backing: Established by Fosun Pharmaceuticals (part of Fosun Group) alongside scientific founders; Fosun group entities remain material shareholders and strategic partners.
• Public ownership: Listed on HKEX (2696.HK), with institutional and retail investors holding free float shares; corporate governance aligned to Hong Kong listing rules.
• Management focus: Executive team and board emphasize R&D investment, regulatory approvals, and global commercialization partnerships.

• Mission: Develop, manufacture and commercialize high-quality biosimilars and oncology/immunology biologics to improve patient access and reduce treatment cost burden.
• Strategic priorities: Expand product portfolio, pursue international registrations and partnerships, scale manufacturing capacity, and sustain R&D pipeline investment.

• R&D model: Internal discovery and development of biosimilars and novel biologics coupled with in‑licensing and co‑development partnerships to accelerate time‑to‑market.
• Manufacturing: GMP biologics manufacturing platforms supporting clinical and commercial supply; emphasis on cost-efficient biologics production at scale.
• Regulatory pathway: Seek approvals through China NMPA, EU/EMA pathways and other national regulators; leverage equivalency and comparability packages for biosimilar approvals.
• Commercial model: Direct commercialization in China for launched products; international commercialization through subsidiaries, distributors and strategic partners.

• Primary revenue: Sales of biologic products (biosimilars and branded biologics) in China and international markets.
• Services and collaborations: R&D service revenue, licensing fees, milestone payments and royalties from partnerships and out‑licensing.
• Cost and profitability drivers: Gross margins driven by scale of manufacturing, product mix (branded vs biosimilar), and pricing dynamics in hospital procurement and reimbursement systems.

• Approved/marketed biosimilars and biologics covering oncology and immunology indications (six China launches, four international launches as of 2025).
• Pipeline: Multiple biosimilar candidates and next‑generation biologics progressing through clinical stages; focus on high‑value oncology and autoimmune targets.

Shanghai Henlius Biotech, Inc. (2696.HK): History

Shanghai Henlius Biotech, Inc. (2696.HK) is a China-based biopharmaceutical company focused on the research, development and commercialization of monoclonal antibody therapeutics. Listed in Hong Kong in 2019, Henlius has concentrated on oncology, autoimmune and other biologics through both in-house development and commercialization partnerships.

• Founded as a biologics R&D and manufacturing company with emphasis on monoclonal antibodies and biosimilars.
• Listed on the Hong Kong Stock Exchange in 2019 (IPO price HK$49.60).
• Has developed and commercialized multiple antibody product candidates and biosimilars for domestic and select international markets.

Ownership and corporate direction have been dominated by Fosun group strategy shifts. For more on investor composition and buying rationale, see: Exploring Shanghai Henlius Biotech, Inc. Investor Profile: Who's Buying and Why?

• Major shareholder: Shanghai Fosun Pharmaceutical (Fosun International subsidiary) - 65.23% ownership.
• June 2024: Fosun International proposed to acquire remaining shares at HK$24.60 per share, valuing Henlius at ~HK$13.37 billion (~US$1.71 billion).
• Offer represented a 30.6% premium to the last traded price prior to the trading halt.
• Since IPO, Henlius shares have fallen over 60% from the HK$49.60 listing price.
• Fosun's buyout cited a strategic refocus to streamline operations and reduce diversification.

How it makes money:

• Product sales of approved monoclonal antibodies and biosimilars in China and select markets.
• Partnered commercialization and licensing deals, including milestone and royalty income.
• Contract manufacturing and development services leveraging biologics production capacity.

Shanghai Henlius Biotech, Inc. (2696.HK): Ownership Structure

• Mission: Provide high-quality, affordable, innovative biologic medicines-prioritizing oncology, autoimmune and ophthalmic diseases-to benefit more patients worldwide. Mission Statement, Vision, & Core Values (2026) of Shanghai Henlius Biotech, Inc.
• Core values: patient-centricity, scientific rigor, accessibility, and global collaboration.
• Strategic focus: build an integrated biopharmaceutical platform combining R&D, GMP-certified manufacturing, and commercialization to shorten time-to-patient and lower cost.

• Integrated capabilities: in-house discovery and translational R&D, clinical development, commercial manufacturing and marketing, plus global regulatory and supply-chain functions.
• Manufacturing & quality: Shanghai-based commercial facilities certified under China, EU and U.S. GMP standards to support global launches and export supply.
• Pipeline breadth: a diversified portfolio covering about 50 molecules across biologics, including monoclonal antibodies, antibody-drug conjugates, biosimilars and novel immuno-oncology assets.
• Lead immuno-oncology strategy: proprietary serplulimab (anti-PD-1 mAb) as backbone for combination regimens exploring multiple tumor types and combination partners.

• Public listing: HKEX ticker 2696.HK (Shanghai Henlius Biotech, Inc.).
• Shareholder base: mix of institutional investors, strategic pharma partners, and public retail holders; management and founders retain meaningful stakes aligned with long-term R&D objectives.
• Governance: board with R&D and commercial expertise, supported by scientific advisory committees for pipeline prioritization and global partnering decisions.

• Product sales: commercial biologics marketed in China and select export markets; revenues from proprietary monoclonal antibodies and biosimilars.
• Licensing & partnerships: out‑licensing, co-development and regional commercialization deals with global pharma/biotech partners for international expansion.
• Milestone & royalty income: clinical, regulatory and sales milestones plus downstream royalties from partnered products.
• Manufacturing services: fee-for-service or contract manufacturing opportunities leveraging GMP-certified facilities.

Shanghai Henlius Biotech, Inc. (2696.HK): Mission and Values

• Integrated biopharmaceutical platform: end-to-end capabilities spanning discovery, clinical development, commercial manufacturing, and global commercialization.
• R&D and global innovation centers: multi-site discovery and translational hubs that feed clinical pipelines and combination-strategy programs.
• Manufacturing and quality: Shanghai-based commercial manufacturing facilities certified to China, EU, and U.S. GMP standards, enabling regulated supply to multiple markets.
• Clinical execution: execution of over 30 clinical studies covering 19 distinct product candidates to date, supporting filings and label expansions across geographies.

• Diversified pipeline: roughly 50 molecules across oncology, immunology, and other therapeutic areas, spanning mAbs, ADCs, biosimilars, and novel biologics.
• Immuno‑oncology focus: proprietary serplulimab (anti‑PD‑1 monoclonal antibody) is a backbone for combination strategies exploring enhanced response rates and indications beyond monotherapy.
• Combination programs: ongoing development of serplulimab with targeted agents, chemotherapy backbones, and other immune modulators to address hard‑to‑treat tumors.

• Clinical reach: more than 30 clinical studies for 19 products, including registrational and exploratory studies in major and emerging markets.
• Commercial launches: six products launched in China and four launched internationally.
• Patient impact: marketed products have benefited over 850,000 patients across nearly 60 countries and regions.

• Shanghai commercial manufacturing sites: multi‑purpose biologics suites for mAbs and complex biologics.
• Regulatory quality: facilities certified by China GMP, EU GMP, and U.S. GMP authorities, enabling global supply chains and cross‑border registrations.

• Product sales: revenues from marketed biologics and biosimilars in China and partner markets.
• Out‑licensing and partnerships: regional licensing deals and co‑development collaborations to accelerate global uptake.
• R&D value realization: milestone payments and potential royalties from late‑stage programs and successful registrations abroad.
• Manufacturing services: fee‑for‑service opportunities leveraging GMP‑certified facilities for contract manufacturing and fill/finish.

• Market presence: marketed in nearly 60 countries and regions through direct commercialization and partner networks.
• Regulatory pathway strategy: use of GMP‑certified Shanghai facilities and global clinical data to support approvals in Asia, Europe, and the Americas.

• Clinical depth: >30 clinical trials supporting 19 product dossiers.
• Scale of benefit: >850,000 patients treated by Henlius products worldwide.
• Pipeline breadth: ~50 pipeline molecules spanning multiple modalities.

Shanghai Henlius Biotech, Inc. (2696.HK): How It Works

• Primary revenue streams: product sales (biosimilars and innovative biologics), R&D services to partners, licensing and milestone/royalty income from collaborations.
• Geographic scope: domestic China commercialization plus international clinical development and license-driven market access across the U.S., EU, Australia, Southeast Asia and Japan.
• Commercial partner network: relationships with 20+ global firms, including Accord, Abbott, Eurofarma, Organon and Sandoz that extend distribution, registration and co-promotion.

• Discovery & preclinical - internal pipelines for mAbs and bispecifics; in-licensed candidates where strategic.
• Clinical development - global clinical trials in the U.S., EU, Australia, Southeast Asia and Japan to support registrations and global labeling.
• Manufacturing - in-house biologics manufacturing capacity for commercial supply, with quality standards suitable for regulated markets.
• Commercialization - direct sales in China and licensing or distribution agreements for ex-China territories.
• Partner services - fee income from contract R&D, tech transfer and manufacturing support to biopharma partners.

• Product sales: commercial biosimilars and innovative biologics sold in China and select external markets (either directly or via licensees).
• Licensing & milestones: upfront licensing fees, clinical and regulatory milestones, and tiered royalties from commercialization partners.
• R&D services: contract research and development, formulation, clinical supply and tech-transfer fees for partner molecules.
• Partnership-driven expansion: strategic licensing agreements that deliver non-dilutive cash via upfront payments and enable Henlius to capture downstream royalties.

• Over 20 global commercial partnerships (e.g., Accord, Abbott, Eurofarma, Organon, Sandoz).
• International clinical development and regulatory programs conducted in the U.S., EU, Australia, Southeast Asia and Japan.
• Multiple out-licensing deals to regional partners for market entry and commercialization support.

• Territorial licensing - partners obtain rights to commercialize specific products in defined territories in exchange for upfront payments, milestones and royalties.
• Co-commercialization - joint promotion or shared commercial responsibilities in select markets to accelerate uptake.
• Manufacturing/tech-transfer agreements - Henlius supplies product or transfers manufacturing know-how to partners under fee or supply contracts.

• Upfront payments and milestones provide near-term non-dilutive cash; royalties provide longer-term, volume-dependent income.
• Regulatory approvals and payer reimbursement decisions in each territory drive revenue ramp and partner-triggered milestones.
• Competition in biosimilar markets and pricing pressures influence product sales and market share.

• Expand out-licensing to additional regions and deepen existing partner agreements to capture royalties and milestones.
• Advance innovative biologics through global registrational trials to unlock premium pricing versus biosimilars.
• Leverage manufacturing capacity to provide contract development and manufacturing services to third parties.

Shanghai Henlius Biotech, Inc. (2696.HK): How It Makes Money

• History & ownership: founded by Chinese biotech entrepreneurs and backed by institutional investors; publicly listed on the Hong Kong Stock Exchange (2696.HK).
• Mission: provide affordable, high-quality biopharmaceuticals and broaden patient access globally.

• Product footprint: six products launched in China and four launched internationally, reaching over 850,000 patients across nearly 60 countries and regions.
• Manufacturing & quality: Shanghai-based commercial manufacturing facilities certified by China, EU and U.S. GMP; global innovation centers support pipeline and partnerships.
• Therapeutic focus: oncology and immunology, with ongoing development of immuno-oncology combinations using serplulimab (anti-PD-1) as backbone.
• Strategic goal: scale international launches and maintain cost-competitive biologics to expand addressable market.

• Drug sales: primary revenue driver-commercialized monoclonal antibodies and biologics sold domestically and internationally.
• R&D services and collaborations: revenue from partner-funded trials, licensing deals and milestone payments tied to co-development and out-licensing.
• Manufacturing services: contract manufacturing and technology transfer leveraging GMP-certified facilities.
• Geographic expansion: international launches and partnership licensing to increase revenue diversification outside China.

• Pipeline advancement-especially serplulimab-based combos-to capture larger oncology indications and combination market share.
• Cost-efficient manufacturing to sustain price competitiveness and margin expansion while scaling patient access.
• Selective global partnerships to accelerate registration and commercialization in multiple regions.